Neurogen cuts jobs

Share this article:
Neurogen said it laid off 70 workers and is taking a charge of about $1.5 million in the first quarter of 2008 to pay severence benefits and other charges.

The move is part of a restructuring to focus resources on advancing its pipeline of insomnia and other compounds including Phase II candidate aplindore for Parkinson's disease and restless legs syndrome.

Neurogen reported a net loss of $40 million for the nine months ended Sept. 30, 2007.
The job cut announcement came just days after Stephen Davis, a lawyer, became president and CEO. Davis succeeds William Koster, who has retired, but remains a director.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.